natgillin/translations-raw huggingface dataset:
No adverse reactions were observed following oral administration to puppies aged 8-9 weeks and weighing 2.0-3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (56 mg, 168 mg and 280 mg fluralaner/kg bodyweight) on three occasions at shorter intervals than recommended (8-week intervals). 
Ko so psičkom, starim 8-9 tednov in težkim 2,0-3,6 kg, dajali lokalno do 5krat večje odmerke od največjega priporočenega (56 mg, 168 mg in 280 mg fluralanerja/kg telesne teže ) trikrat v krajših razmikih, kot je priporočeno (8-tedenski razmiki), niso opazili nobenih neželenih učinkov.
Bravecto should be administered in accordance with the following table (corresponding to a dose of 25-56 mg fluralaner/kg bodyweight within one weight band): 
Bravecto je treba dajati v skladu z naslednjo preglednico (en odmerek 25-56 mg fluralanerja /kg telesne teže v eni skupini):
Bravecto should be administered in accordance with the following table (corresponding to a dose of 25-56 mg fluralaner/kg body weight): 
Bravecto je treba dajati v skladu z naslednjo preglednico (en odmerek 25-56 mg fluralanerj/kg telesne teže):
During laboratory and clinical field testing, no interactions between Bravecto spot-on solution for cats and routinely used veterinary medicinal products were observed. 
Med laboratorijskimi in kliničnimi testiranji niso opazili medsebojnih delovanj med zdravilom Bravecto kožni nanos, raztopina za mačke, in drugimi zdravili za uporabo v veterinarski medicini, ki se uporabljajo rutinsko.
QUANTITY OF THE ACTIVE SUBSTANCE(S) 
KOLIČINA UČINKOVIN(E) fluralaner
During laboratory and clinical field testing, no interactions between Bravecto spot-on solution for dogs and routinely used veterinary medicinal products were observed. 
Med laboratorijskimi in kliničnimi testiranji niso opazili medsebojnih delovanj med zdravilom Bravecto kožni nanos, raztopina za pse in drugimi zdravili za uporabo v veterinarski medicini, ki se uporabljajo rutinsko.
Pregnancy, lactation and fertility: The veterinary medicinal product can be used in breeding, pregnant and lactating dogs. 
4.7 Uporaba v obdobju brejosti, laktacije ali nesnosti Varnost zdravila za uporabo v veterinarski medicini pri psih za vzrejo, v dobi brejosti in laktacije je bila dokazana.
Hypersensitivity reactions to the product have been reported in a small number of people. 
Pri majhni skupini ljudi so poročali o preobčutljivostnih reakcijah pri drugem zdravilu za uporabo v veterinarski medicini.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Sachet 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
The product contributes towards the control of the environmental flea populations in areas to which treated cats have access. 
Zdravilo prispeva k obvladovanju okoljske populacije bolh na področjih, kamor imajo dostop zdravljene mačke.
Mild and transient skin reactions at the application site, such as erythema and pruritus or alopecia were commonly observed in clinical trials (2.2% of treated cats). 
Blage in prehodne kožne reakcije na mestu nanosa kot na primer rdečina in srbenje ali izpadanje dlake so pogosto opaženi med kliničnimi testiranji ( 2,2% zdravljenih mačk).
Mild and transient skin reactions at the application site such as erythema or alopecia were commonly observed in clinical trials (1.2% of treated dogs). 
Blage in prehodne kožne reakcije na mestu nanosa kot na primer rdečina ali izpadanje dlake so pogosto opaženi med kliničnimi testiranji ( 1,2% zdravljenih psov).
The product contributes towards the control of the environmental flea populations in areas to which treated dogs have access. 
Zdravilo prispeva k obvladovanju okoljske populacije bolh na področjih, kamor imajo dostop zdravljeni psi.
Dimethylacetamide Glycofurol 
Seznam pomožnih snovi dimetilacetamid glikofurol dietiltoluamid ( DEET) aceton
Bravecto 112.5 mg chewable tablets for very small dogs (2-4.5 kg) Bravecto 250 mg chewable tablets for small dogs (>4.5-10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs (>10-20 kg) Bravecto 1,000 mg chewable tablets for large dogs (>20-40 kg) Bravecto 1,400 mg chewable tablets for very large dogs (>40-56 kg) 
Bravecto 112,5 mg žvečljive tablete za zelo majhne pse (2-4,5 kg) Bravecto 250 mg žvečljive tablete za majhne pse (>4.5-10 kg) Bravecto 500 mg žvečljive tablete za srednje velike pse (>10-20 kg) Bravecto 1000 mg žvečljive tablete za velike pse (>20-40 kg) Bravecto 1400 mg žvečljive tablete za zelo velike pse (>40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2-4.5 kg) Bravecto 250 mg chewable tablets for small dogs (>4.5 -10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs (>10-20 kg) Bravecto 1,000 mg chewable tablets for large dogs (>20-40 kg) Bravecto 1,400 mg chewable tablets for very large dogs (>40-56 kg) 
Bravecto 112.5 mg žvečljive tablete za zelo majhne pse (2-4,5 kg) Bravecto 250 mg žvečljive tablete za majhne pse (>4.5-10 kg) Bravecto 500 mg žvečljive tablete za srednje velike pse (>10-20 kg) Bravecto 1000 mg žvečljive tablete za velike pse (>20-40 kg) Bravecto 1400 mg žvečljive tablete za zelo velike pse (>40-56 kg)
PACKAGE LEAFLET: Bravecto 112.5 mg spot-on solution for small cats (1.2 - 2.8 kg) Bravecto 250 mg spot-on solution for medium-sized cats (>2.8 - 6.25 kg) Bravecto 500 mg spot-on solution for large cats (>6.25 - 12.5 kg) 
NAVODILO ZA UPORABO: Bravecto 112,5 mg kožni nanos, raztopina za majhne mačke (1,2 - 2,8 kg) Bravecto 250 mg kožni nanos, raztopina za srednje velike mačke (>2,8 - 6,25 kg) Bravecto 500 mg kožni nanos, raztopina za velike mačke (>6,25 - 12,5 kg)
Pipette content (ml) 
Volumen (ml)
Bravecto 112.5 mg spot-on solution for small cats (1.2 - 2.8 kg) Bravecto 250 mg spot-on solution for medium-sized cats (>2.8 - 6.25 kg) Bravecto 500 mg spot-on solution for large cats (>6.25 - 12.5 kg) fluralaner 
Bravecto 112.5 mg kožni nanos, raztopina za majhne mačke (1,2 - 2,8 kg) Bravecto 250 mg kožni nanos, raztopina za srednje velike mačke (>2,8 - 6,25 kg) Bravecto 500 mg kožni nanos, raztopina za velike mačke (>6,25 - 12,5 kg) fluralaner
There were no findings on reproductive performance and no findings of concern on offspring viability when fluralaner was administered orally to Beagle dogs at overdoses of up to 3 times the maximum recommended dose (up to 168 mg/kg bodyweight of fluralaner). 
Ko so fluralaner dajali peroralno biglom v odmerkih, ki so bili do 3krat večji od največjega priporočenega odmerka (do 168 mg fluralanerja na kg telesne teže), niso ugotovili vplivov na reprodukcijo in tudi ne zaskrbljujočih vplivov na življenjsko sposobnost potomcev.
0.4 ml 0.89 ml 1.79 ml 
VSEBINA PO TEŽI, VOLUMNU ALI ŠTEVILU ODMERKOV 0,4 ml 0,89 ml 1,79 ml
CONTRAINDICATIONS 
KLINIČNI PODATKI
The acknowledgement form needs to be provided by physicians to all patients, including those currently on treatment. 
Potrditveni obrazec morajo zdravniki posredovati vsem bolnikom, vključno s tistimi, ki se trenutno že zdravijo.
The existing educational materials should also be updated with these recommendations and complemented with an acknowledgement form. 
Obstoječe izobraževalno gradivo je prav tako treba posodobiti s temi priporočili in ga dopolniti s potrditvenim obrazcem.
The educational material in place should also be updated. 
Posodobiti je treba tudi obstoječe izobraževalno gradivo.
This view was supported by the PRAC who recommended that this stricter discontinuation criterion, regardless of bilirubin levels, should be applied. 
Odbor PRAC je podprl to stališče in priporočil, da se uporabi strožji kriterij za prekinitev, ne glede na ravni bilirubina.
The PRAC also considered the views expressed by experts consulted during the course of the procedure (scientific advisory group (SAG) on neurology). 
Odbor PRAC je proučil tudi stališča strokovnjakov, s katerimi se je posvetoval med postopkom (znanstvena svetovalna skupina (SAG) za nevrologijo).
Patients should also be explained the importance of adhering to the periodic liver monitoring. 
Bolnikom je treba tudi pojasniti, kako pomembno se je držati rednega spremljanja delovanja jeter.
On 9 June 2017 the EC therefore triggered a procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data, and requested the PRAC to assess the impact of the above concerns on the benefit-risk balance of Zinbryta (daclizumab) and to issue a recommendation on whether the marketing authorisation should be maintained, varied, suspended or revoked. 
Zato je Evropska komisija 9. junija 2017 na podlagi farmakovigilančnih podatkov sprožila postopek v skladu z členom 20 Uredbe (ES) št. 726/2004 in odbor PRAC zaprosila, da oceni vpliv zgoraj navedenih pomislekov na razmerje med tveganji in koristmi zdravila Zinbryta (daklizumab) ter izda priporočilo o tem, ali naj se dovoljenje za promet z zdravilom ohrani, spremeni, začasno umakne ali ukine.
Subgroup analyses of these studies, although of limited robustness, did not identify statistically significant differences in key efficacy outcomes in MS patients with high disease activity compared to patients with low disease activity. 
Analize podskupin pri teh študijah so imele sicer omejeno robustnost, vendar z njimi niso prepoznali statistično značilnih razlik v ključnih izidih učinkovitosti pri bolnikih z MS z visoko aktivno boleznijo v primerjavi z bolniki z nizko aktivno boleznijo.
The PRAC also considered the views expressed by the scientific advisory group on neurology. 
Odbor PRAC je proučil tudi stališča znanstvene svetovalne skupine za nevrologijo;
Patients tested positive should be recommended to consult with a physician with expertise in the treatment of these conditions. 
Priporočljivo je, da se bolniki s pozitivnim rezultatom preiskave posvetujejo z zdravnikom, ki ima izkušnje z zdravljenjem teh bolezni.
In addition the frequency of transaminase increases and liver function tests abnormal should be updated to very common. 
Poleg tega je treba pogostnost testiranj zvišanja ravni transaminaz in nenormalnega delovanja jeter posodobiti na zelo pogosto.
• The PRAC considered the procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data for Zinbryta (daclizumab). 
• odbor PRAC je obravnaval postopek v skladu s členom 20 Uredbe (ES) št. 726/2004, ki je bil na podlagi farmakovigilančnih podatkov sprožen za zdravilo Zinbryta (daklizumab);
The PRAC thus considered that further measures are needed to minimise this risk including limiting the use of the product to situations where no other therapeutic options are suitable. 
Odbor PRAC je zato menil, da so potrebni nadaljnji ukrepi za zmanjšanje tega tveganja, vključno z omejitvijo uporabe zdravila na primere, pri katerih ni primerna nobena druga možnost zdravljenja;
Daclizumab is not expected to be metabolised by the liver and the experts noted that it would be unfeasible to completely exclude hepatotoxic medications from the clinical management of MS patients. 
Ni pričakovati, da bi se daklizumab presnavljal v jetrih, in strokovnjaki so opozorili, da ne bi bilo primerno popolnoma izključiti hepatotoksičnih zdravil iz klinične obravnave bolnikov z MS.
To facilitate the discussion between physicians and patients on this topic and ensure patients have understood information provided on the risk, following the view of the SAG, the PRAC required the introduction of an acknowledgment form. 
Za lažjo komunikacijo med zdravniki in bolniki o tej temi in za zagotavljanje, da so bolniki razumeli informacije o tveganju, je skladno s stališčem znanstvene svetovalne skupine odbor PRAC zahteval uvedbo potrditvenega obrazca.
Patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) were excluded from clinical trials and no correlation has been established between pre-existing infections with these viruses and daclizumab-induced serious liver injury at present. 
Bolniki z virusom hepatitisa C (HCV) ali hepatitisa B (HBV) so bili izključeni iz kliničnih preskušanj in zaenkrat še niso ugotovili obstoja povezave med obstoječimi okužbami s temi virusi in poškodbami jeter, ki jih povzroča daklizumab.
• The PRAC also considered it necessary to introduce an acknowledgement form to ensure patients have been adequately informed on the risks of liver injury associated to daclizumab. 
• odbor PRAC je presodil tudi, da je treba uvesti potrditveni obrazec za zagotavljanje, da so bili bolniki ustrezno seznanjeni o tveganjih za poškodbe jeter, povezane z daklizumabom.
No time window of a higher risk could be identified and cases of liver injury have occurred throughout treatment and up to 6 months after the last dose of daclizumab. 
Prepoznati ni bilo mogoče nobenega časovnega okna za povečano tveganje in primeri poškodb jeter so se pojavljali ves čas zdravljenja in do šest mesecev po zadnjem odmerku daklizumaba.
• In addition, prior to treatment initiation, patients should be screened for hepatitis B and C infection and initiation is not recommended in patients with other autoimmune conditions. 
• poleg tega je treba bolnike pred uvedbo zdravljenja presejati tudi glede okužbe s hepatitisom B in C, uvedba zdravljenja pa pri bolnikih z drugimi avtoimunskimi stanji ni priporočljiva.
These clinical effects were supported by robust and substantial treatment effects in reducing all key brain magnetic resonance imaging (MRI) parameters of acute and chronic inflammatory and destructive central nervous system disease activity. 
Ti klinični učinki so bili podprti z obsežnimi in precejšnjimi učinki zdravljenja pri zmanjševanju vseh ključnih parametrov akutne in kronične vnetne aktivnosti bolezni in uničevanja osrednjega živčnega sistema pri magnetnoresonančnem slikanju (MRS) možganov.
The CHMP concluded that the summary of products characteristics should be amended accordingly. 
Odbor CHMP je zaključil, da je treba v skladu s tem posodobiti povzetek glavnih značilnosti zdravila.
Finally the threshold of transaminases elevation for patients not included in clinical trials, and therefore in which treatment initiation is not recommended, should be corrected from above two times the upper normal limit to above or equal to two times that limit. 
Končno je treba prag dviga vrednosti transaminaz pri bolnikih, ki niso vključeni v klinična preskušanja, in zato pri njih uvedba zdravljenja ni priporočena, popraviti z več kot dvakratne vrednosti zgornje normalne meje na več ali enako dvakratni vrednosti te meje.
Although it was recognised that this measure has no predictive value on the risk of developing severe and potential fatal liver injury, the SAG considered that as a precautionary measure discontinuation of therapy should be recommended when patients levels of ALT or AST reach over 3 times the upper limit of normal. 
Čeprav je bilo sprejeto, da ta ukrep nima napovedne vrednosti na tveganje za razvoj resne in potencialno usodne poškodbe jeter, je znanstvena svetovalna skupina menila, da je treba kot previdnostni ukrep priporočiti prekinitev zdravljenja, kadar ravni ALT ali AST pri bolnikih presežejo trikratno zgornjo mejo normalne vrednosti.
Discontinuation should also be considered if an adequate response has not been achieved or if the liver function monitoring is not adhered to. 
O prekinitvi zdravljenja je treba razmisliti tudi ob nedoseganju zadostnega odziva ali neupoštevanju spremljanja delovanja jeter.
On 7 June 2017, the European Commission (EC) was informed of a fatal case of fulminant liver failure in a patient treated with daclizumab in an ongoing observational study, despite monthly liver function testing performed in accordance with recommendations in the product information. 
Evropska komisija je 7. junija 2017 prejela obvestilo o smrtnem primeru zaradi fulminantne odpovedi jeter pri bolniku, zdravljenim z daklizumabom v okviru tekoče opazovalne študije, kljub mesečnim pregledom delovanja jeter v skladu s priporočili v informacijah o zdravilu.
It was also noted that autoimmune thyroiditis was reported in the recent fatal case as well as in one of the adjudicated cases. 
Opozorili so tudi, da so v nedavnem usodnem primeru in v enem od primerov, o katerih se presoja, poročali o avtoimunskem tiroiditisu.
Overall, considering the data available, the occurrence of daclizumab induced liver injury is considered to be unpredictable. 
Z upoštevanjem razpoložljivih podatkov velja pojav z daklizumabom povzročenih poškodb jeter za nepredvidljivega.
• In addition, the PRAC recommended strengthening the current warnings to take due account that liver functions, including bilirubin levels, of all patients should be monitored at least monthly, close to each administration of daclizumab, and for six months after end of treatment and stricter discontinuation criteria in case of elevated transaminase should now be applied. 
• poleg tega je odbor PRAC priporočil okrepitev trenutnih opozoril, da je treba delovanje jeter, vključno z ravnmi bilirubina, pri vseh bolnikih spremljati vsaj mesečno, blizu časa dajanja daklizumaba, in še šest mesecev po koncu zdravljenja in da je treba zdaj uporabljati strožja merila za prekinitev zdravljenja v primeru zvišanih vrednosti transaminaz.
The description of hepatic injury in the product information should be brought up to date in line with current knowledge. 
Opis poškodb jeter v informacijah o zdravilu je treba posodobiti glede na trenutno vedenje.
As the risk has been shown to persist for up to six months after the last dose of daclizumab, this monitoring should be continued for the same period after the end of treatment. 
Ker so dokazali, da tveganje traja še do šest mesecev po zadnjem odmerku daklizumaba, je treba spremljanje nadaljevati še šest mesecev po koncu zdravljenja.
Cases of liver injury were identified both through signs and symptoms and through laboratory values, therefore patient serum transaminase and total bilirubin levels should be monitored at least monthly and as close as possible before each administration, and more frequently if clinically indicated during treatment. 
Primere poškodb jeter so prepoznali s pomočjo znakov in simptomov ter z laboratorijskimi preiskavami, zato je treba ravni transaminaze in skupnega bilirubina v serumu pri bolnikih spremljati vsaj mesečno in čim bližje posameznemu odmerku ter pogosteje, če se med zdravljenjem izkaže, da je to klinično indicirano.
The PRAC concluded therefore that caution should be exercised when using such medicines concomitantly with daclizumab. 
Odbor PRAC je zato zaključil, da je pri uporabi tovrstnih zdravil hkrati z daklizumabom potrebna previdnost.
The efficacy of daclizumab was demonstrated in two pivotal studies in subjects with relapsing remitting multiple sclerosis (RRMS) that led to the indication in relapsing multiple sclerosis. 
Učinkovitost daklizumaba je bila dokazana v dveh ključnih študijah na subjektih z recidivnoremitentno multiplo sklerozo (RRMS), kar je vodilo v sprejetje indikacije za zdravljenje recidivne multiple skleroze.
• The PRAC concluded that daclizumab is associated, during the treatment and for several months after the end of treatment, with an unpredictable and potentially fatal risk of immune-mediated liver injury. 
• Odbor PRAC je zaključil, da je daklizumab med zdravljenjem in še več mesecev po koncu zdravljenja povezan z nepredvidljivim in potencialno usodnim tveganjem za imunsko posredovane poškodbe jeter.
Taking into account the conclusions from the SAG that the use of the medicinal product should be restricted to patients who are unsuitable for treatment with other disease modifying therapies (DMTs), the PRAC considered that the identification of sub-groups within the target population (i.e. with highly active disease and with rapidly evolving severe disease) was not warranted and that the restriction of the use would apply to all patients with RMS who are unsuitable for treatment with other DMT. 
Z upoštevanjem zaključkov znanstvenega svetovalnega odbora, da je treba uporabo zdravila omejiti na bolnike, ki so neprimerni za zdravljenje z drugimi zdravili, ki spreminjajo potek bolezni (DMT), je odbor PRAC presodil, da ugotavljanje podskupin v okviru ciljne populacije (tj. podskupin z visoko aktivno boleznijo in hitro napredujočo hudo boleznijo) ni upravičeno in da bo omejitev uporabe veljala za vse bolnike z RMS, ki so neprimerni za zdravljenje z drugimi zdravili DMT.
The PRAC noted that a fatal case had occurred despite the risk minimisation measures already implemented, including monthly liver monitoring. 
Odbor PRAC je opozoril, da je do usodnega primera prišlo kljub že izvajanim ukrepom za zmanjšanje tveganja, vključno z mesečnim spremljanjem delovanja jeter.
Results from both studies demonstrated clinically meaningful and statistically significant reductions in relapse rate, the primary efficacy endpoint in each study. 
Rezultati obeh študij so dokazali klinično pomembno in statistično značilno zmanjšanje števila recidivov, kar je bilo v obeh študijah primarni opazovani dogodek.
The PRAC thus considered that further measures to those implemented as part of the provisional measures were justified to minimise this risk and, in view of its unpredictable and potentially fatal nature, to limit the use of the medicinal product. 
Odbor PRAC je zato presodil, da so za zmanjšanje tega tveganja poleg ukrepov, ki se že izvajajo v okviru začasnih ukrepov, utemeljeni še dodatni ukrepi, glede na nepredvidljivo in potencialno usodno naravo pa je utemeljena tudi omejitev uporabe tega zdravila.
Daclizumab treatment also resulted in clinically meaningful slowing of the accumulation of neurological disability as measured by both clinician-assessed and patient-reported outcome measures. 
Zdravljenje z daklizumabom je povzročilo tudi klinično pomembno upočasnitev napredovanja nevrološke invalidnosti, merjene z izidi, kot jih je ocenil zdravnik in kot jih je navajal bolnik.
Transaminases elevations and serious hepatic injury are known risks associated to treatment with Zinbryta (daclizumab) and several risk minimisation measures (RMMs) were implemented in this regard at the time of the initial marketing authorisation, including monthly liver function monitoring. 
Dvig ravni transaminaz in resne poškodbe jeter so znana tveganja pri zdravljenju z zdravilom Zinbryta (daklizumab), zaradi česar so bili v času izdaje prvotnega dovoljenja za promet z zdravilom uvedeni številni ukrepi za zmanjševanje teh tveganj (RMM), vključno z mesečnim spremljanjem delovanja jeter.
Based on the limited data available, any synergistic hepatotoxic effects in patients taking concomitant hepatotoxic medications on the liver injury caused by daclizumab could not be fully elucidated. 
Ker so razpoložljivi podatki omejeni, sinergistični hepatotoksični učinki pri bolnikih, ki jemljejo tudi druga hepatotoksična zdravila, na poškodbe jeter, ki jih povzroča daklizumab, niso bili popolnoma pojasnjeni.
The PRAC concluded that daclizumab is associated with a potentially fatal risk of immune-mediated liver injury. 
Odbor PRAC je zaključil, da je daklizumab povezan s potencialno usodnim tveganjem za imunsko posredovane poškodbe jeter.
The PRAC also considered that daclizumab should be contraindicated in patients with pre-existing hepatic disease or impairment. 
Odbor PRAC prav tako meni, da mora biti daklizumab kontraindiciran pri bolnikih s predhodno obstoječo boleznijo ali okvaro jeter;
Zinbryta (daclizumab) is a centrally authorised medicinal product indicated at the start of this review in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS). 
Zinbryta (daklizumab) je zdravilo, ki je odobreno po centraliziranem postopku in na začetku tega pregleda namenjeno zdravljenju recidivnih oblik multiple skleroze pri odraslih bolnikih.
Administration of daclizumab with other medicinal products of known hepatotoxic potential should be done with caution. 
Daklizumab je treba dajati previdno skupaj z drugimi zdravili z znanim hepatotoksičnim potencialom;